INTRODUCTION

The COVID-19 pandemic is associated with a variety of neurological symptoms. In the course of COVID-19 infection, hypercoagulability occurs that is likely a ‘sepsis-induced coagulopathy’ and may predispose to stroke. The clinical course of COVID-19 is most severe in elderly patients, in men, and in patients with comorbidities as diabetes mellitus, obesity, hypertension and most cardiovascular risk factors. The data from the ‘first wave’ of SARS-CoV-2 pandemic show that the rates of stroke in hospitalized patients with COVID-19 range from 1% to 3% and up to 6% of critically ill patients. Strokes course in patients with COVID-19 may be more severe and associated with higher in-hospital mortality and disability on discharge.

Intravenous thrombolysis (IVT) with the use of recombinant tissue plasminogen activator is an effective and universally recommended method of treatment in the acute ischaemic stroke (AIS).
inflammatory processes predict poor outcomes in ischaemic stroke treated with IVT, and pneumonia especially predicts increasing mortality in these patients. However, only a few reports associated the impact of SARS-CoV-2 infection on the outcome of patients treated with IVT. Therefore, our objectives were to determine short time safety and efficacy of IVT in patients with AIS and COVID-19.

2 | METHODS

2.1 | Study design

We conducted a retrospective observational study based on hospital-based stroke registries from Department of Neurology and Stroke Unit of Holy Spirit Specialist Hospital in Sandomierz, Department of Neurology and Stroke Unit of Regional Hospital in Kielce, Department of Neurology and Stroke Unit of Saint Lukas Hospital in Końskie and Department of Neurology and Stroke Unit of Skłodowska-Curie Hospital in Skarżysko-Kamienna located in Świętokrzyski region in Poland. Those stroke centres are equipped with the proper monitoring and diagnostic facilities and provide a 24-h stroke service seven days a week. In the stroke units, diagnostic and treatment procedure protocols with respect to unified regular protocols of the management of AIS, according to the Polish national and international recommendations, are in force. The ethics committee approved all data of analysis (Ethics Committee of Jan Kochanowski University in Kielce, Number 17/2020).

2.2 | Study population

Study population consisted of 70 Caucasian adults (51.4% of males, mean age 72, 7 ± 12 years)—all of those patients who were treated only with IVT between 15 September 2020 and 30 November 2020 (14.8% of 473 subjects with AIS consecutively hospitalized in study stroke units in recruitment period).

The severity of stroke symptoms was assessed using the National Institute of Health Stroke Scale (NIHSS) by stroke physician at admission to Emergency Departments. Stroke onset was defined as the last occasion on which the patient was known to be without neurological deficit. Brain computed tomography (CT) and/or magnetic resonance were performed upon admission to hospitals in order to establish the indication for treatment and between 22 and 36 h after treatment. Examinations to evaluate the inflammatory processes and the coagulation status and also chest X-ray and/or chest CT in all patients were performed. To evaluate the aetiology of the stroke transcranial doppler, carotid duplex ultrasonography, Holter electrophysiology and transthoracic echocardiography were performed. The stroke outcomes were measured using the modified Rankin scale (mRS). A favourable outcome was measured as an mRS score ≤2 points, whilst an unfavourable outcome was defined as an mRS score of 3–6 points. Symptomatic intracerebral haemorrhage rates were assessed according to the ECASS II (European Cooperative Acute Stroke Study II) and III criteria. To determine the type of ischaemic strokes, the TOAST (trial of ORG 10172 in acute stroke treatment) classification was also taken from the discharge summary.

2.3 | Definition of stroke patients with SARS-CoV-2

All patients were tested for COVID-19 with the reverse transcriptase-polymerase chain reaction tests. For SARS-CoV-2-infected group, we included patients with positive test performed within 3 days of admission.

2.4 | Statistical analysis

This study was based on a retrospective database analysis. Data gathering, characteristics and univariate analysis were performed using Microsoft Excel 2017; statistical analysis was performed with STATISTICA v. 9.1. All continuous variables were tested for a normal distribution and equality of variances. Because of the non-normality of the variables, non-parametric Mann-Whitney U tests were used to perform the univariate analysis of the continuous variables. Categorical data were compared using chi-square tests; p-values <.05 were considered statistically significant. The multivariate analysis was performed using multiple logistic regression models. Three separate models, each excluding correlating variables, were done. Factors identified in the univariate analysis with a p value <.01 were then examined using a multivariate models. Each model was created taking into account the correlation between the individual continuous variables.

3 | RESULTS

Patients infected COVID-19 were characterized by higher median of baseline NIHSS, lower percentage of diagnosis ‘minor stroke’ (NIHSS 1–5 pts.) and higher presence of pneumonia. Patients with COVID-19 stayed in the hospital longer. There was no difference between pre- and in-hospital delays, risk factors profile, presence of fever at admission and complications rate between the two groups. Median of D-dimers was higher in COVID than in non-COVID patients; no other differences of biochemical parameters between patients with and without COVID infection existed. Proportion of patients functionally independent (mRS 0–2) on discharge tended to be lower in patients with COVID infection; in-hospital mortality did not differ between both groups (Table 1).

However, there were no differences regarding presence of COVID infection between patients with favourable (mRS 0–2 pts) and unfavourable hospital outcome (mRS 3–6 pts) (22.9% vs. 40%, p =.12). Stroke survivors functionally independent on discharge were characterized by younger age (69.2 ± 11.4 vs. 77.4 ± 10.1 years,
TABLE 1  The clinical characteristics of the of stroke patients with and without COVID infection treated with iv-thrombolysis

| Variables                                      | With COVID infection | Without COVID infection | p-value |
|------------------------------------------------|----------------------|-------------------------|---------|
| n(%)                                           | 22(31)               | 48(69)                  | -       |
| Age (mean; SD) (years)                        | 74.5(±7.9)           | 72.9(±12.8)             | .60     |
| Gender (male) n(%)                            | 15(65.5)             | 21(42.0)                | .10     |
| NIHSS on admission (median; range) [points]   | 11(3–20)             | 6.5(2–25)               | <.01    |
| 'Minor' stroke symptoms (NIHSS 1–5 pts) n(%)  | 2(9.1)               | 18(37.5)                | <.01    |
| Onset to treatment time (mean, SD) (min)      | 177(±60)             | 191(±51)                | .34     |
| 'Door to needle' time (median, range) (min)   | 52(15–123)           | 61(10–170)              | .12     |
| SBP on admission (median; range) (mmHg)       | 148(100–230)         | 151(112–250)            | .22     |
| DBP on admission (median; range) (mmHg)       | 84(70–120)           | 81(52–130)              | .65     |
| Heart rate on admission (median; range) (beats/min) | 85(68–134)     | 80(55–120)              | .41     |
| Saturation (median; range) (%)                | 93(60–98)            | 95(60–99)               | .06     |
| Pneumonia n(%)                                | 11(47.8)             | 6(12)                   | <.01    |
| Fever on admission n(%)                       | 2(22.2)              | 4(14.5)                 | .45     |
| Hyperlipidemia n(%)                           | 9(40.9)              | 25(52.8)                | .38     |
| Antibiotic prior admission                    | 2(10.5)              | 1(2.0)                  | .38     |
| Diabetes Mellitus n(%)                        | 8(33.3)              | 8(16.0)                 | .10     |
| Current smoking n(%)                          | 2(10.5)              | 5(10)                   | .70     |
| Arterial hypertension n(%)                    | 8(33.3)              | 8(16)                   | .09     |
| BMI ≥26 kg/m²                                  | 12(54.6)             | 18(37.5)                | .18     |
| Previous myocardial infarction n(%)           | 2(10.5)              | 4(8.0)                  | .74     |
| Carotid stenosis >50% or occlusion n(%)       | 3(13.6)              | 10(20.83)               | .46     |
| Atrial fibrillation n(%)                      | 5(20.8)              | 7(14)                   | .46     |
| Statin therapy before stroke n(%)             | 4(18.2)              | 14(29.2)                | .32     |
| Antiplatelet therapy before stroke n(%)       | 5(26.3)              | 17(34)                  | .53     |
| NOAC therapy before stroke n(%)               | 0                    | 1(2)                    | .61     |
| VKA therapy before stroke n(%)                | 0                    | 1(2)                    | .61     |
| Lacunar aetiology of stroke n(%)              | 8(33.3)              | 7(14)                   | .06     |
| Old ischaemic lesions in CT on admission n(%) | 7(36.8)              | 21(42.9)                | .65     |
| CRP (median; range) (µg/ml)                   | 25.9(0.39–234)       | 2.83(0.32–9.32)         | .07     |
| Fibrinogen (mean, SD) (mg/dl)                 | 390(±159)            | 341(±188)               | .60     |
| D-dimers (median; range) (ng/ml)              | 870(386–34300)       | 570(250–2296)           | .03     |
| eGFR (mean, SD) (ml/min/m2)                   | 72(±24)              | 64(±19)                 | .19     |
| WBC (median; range) (10³/µl)                  | 8.2(3.4–13.8)        | 8.6(4.9–29.3)           | .29     |
| PLT (median; range) (10³/µl)                  | 214(127–408)         | 231(108–565)            | .48     |
| HGB (median; range) (g/dl)                    | 14.1(10.8–15.6)      | 13.6(4.39–15.9)         | .10     |
| Glucose (median; range) (mg%)                 | 118(77–359)          | 127(83–349)             | .60     |
| sICH                                           | 1(4.55)              | 0                       | .68     |
| mRS 0–2 pts. at discharge n(%)                | 8(33.3)              | 27(56.2)                | .06     |
| Length of stay in hospital (median; range) (days) | 17(1–39)          | 9(1–16)                 | <.01    |
| Death within hospitalization n(%)             | 5(20.8)              | 5(12)                   | .33     |

Abbreviations: BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HGB, haemoglobin; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NOAC, novel oral anticoagulants; PLT, platelets; pts, points; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation; sICH, symptomatic intracerebral haemorrhage; VKA, vitamin K antagonists; WBC, white blood cells.

*p <.01*, lower baseline NIHSS score (6.0, 2–12 vs. 12.0, 3–25 pts, p <.01), or CRP level (3.4, 0.4–269 vs. 27.5, 0.7–264 µg/ml, p = .02) and less frequent history of carotid stenosis (5.7 vs. 31.4%, p = .01) or atrial fibrillation (5.7% vs. 28.6%, p = .01) than those with functional dependency or death prior discharge. They were also characterized by higher proportion of patients with lacunar stroke (31.4%
vs. 11.4%, \( p = .04 \) or body mass index (BMI) ≥26 kg/m\(^2\) (57.1% vs. 28.6%, \( p = .01 \)) and a higher baseline percentage of saturation on admission than patients with mRS 3–6 pts (96, 81–99 vs. 93, 60%–98%, \( p < .01 \)). Initial saturation was also higher amongst stroke survivors than those who died during hospitalization (96, 81–99 vs. 90, 60%–96%, \( p < .01 \)). No other differences between patients with and without favourable clinical outcome were found; significant correlations between CRP and saturation or NIHSS score on admission and between saturation and door-to-needle time or NIHSS score on admission in studied group existed (Table 2).

Multivariate logistic regression models showed that only baseline NIHSS, higher age and presence of carotid stenosis had an impact on patients’ outcome on discharge (Table 2).

4 | DISCUSSION

The results of our study indicate that routinely performed IVT had similar short-term efficacy and safety profile in patients with COVID-19 as in patients without COVID-19. Our findings are similar to the observation of the Chinese patients from Wuhan by Zhou et al.\(^ {22} \) However, there is not much information available about IVT in Caucasian AIS patients infected with SARS-CoV-2 to date, and previously published reports analysed small groups of patients and did not include a control groups or they were case reports.\(^ {12–15} \) To the best of our knowledge, in addition to our study there is only one more based on multicentre consecutive recruitment in regional hospitals.\(^ {8} \)

In our AIS patients treated with IVT infected with COVID-19 ischaemic strokes were more severe than in the controls and in the infected group, there were lower percentage of the diagnosis of ‘minor strokes’. Similarly, AIS were more severe in the group of patients from the UK multicentre case-control study.\(^ {4} \) Pooled analysis of all consecutive patients hospitalized with laboratory-confirmed COVID-19 and AIS in 28 sites from 16 countries (The Global COVID-19 Stroke Registry) published by Ntaios et al. founded that AIS patients infected with COVID-19 had significantly greater stroke severity according to NIHSS scale and had higher risk for severe disability and death compared with patients without COVID-19.\(^ {23} \) Higher baseline NIHSS and higher in-hospital mortality rate in patients with stroke and COVID-19 confirmed also meta-analysis by Nannoni et al.\(^ {24} \)

| TABLE 2 | Multivariate logistic regression models showing factors for unfavourable hospital outcome (mRS 3–6 pts) |
|-----------------|-----------------|-----------------|-----------------|
| **Model 1** | **Model 2** | **Model 3** |
| **OR (95%CI)** | **p** | **OR (95%CI)** | **p** | **OR (95%CI)** | **p** |
| COVID–19 infection | 0.47 | (0.09–2.6) | .39 | 0.21 | (0.04–1.03) | .05 | 0.26 | (0.06–1.20) | .08 |
| Lacunar aetiology of stroke | 5.35 | (0.44–65.4) | .18 | 3.4 | (0.57–20.1) | .17 | 2.75 | (0.48–15.8) | .26 |
| Atrial fibrillation | 0.17 | (0.02 – 1.28) | .09 | 0.31 | (0.05–1.89) | .21 | 0.36 | (0.06–2.39) | .29 |
| Carotid stenosis | 0.12 | (0.01–1.13) | .07 | 0.15 | (0.02–1.29) | .08 | 0.08 | (0.01–0.71) | .02 |
| BMI ≥26 kg/m\(^2\) | 2.44 | (0.49–12.0) | .27 | 1.9 | (0.46–7.8) | .36 | 2.38 | (0.62–9.25) | .21 |
| Age (years) | 1.13 | (1.03–1.24) | <.01 | 1.1 | (1.0–1.2) | <.01 | 1.1 | (1.01–1.16) | .02 |
| NIHSS score on admission\(^ {4} \) (pts) | 1.5 | (1.15–1.95) | <.01 | - | - | - | - | - |
| CRP\(^ {4} \) (µg/ml) | - | - | 1.0 | (0.99–1.1) | .25 | - | - | - |
| Saturation\(^ {4} \) % | - | - | - | - | 0.89 | (0.79–1.00) | .06 |

Abbreviations: BMI, body mass index; CRP, C-reactive protein; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.

\(^ {4} \)Correlations in studied group: CRP versus Saturation: \( R = −0.26 \ p = .03 \); CRP versus NIHSS score on admission: \( R = −0.34 \ p < .01 \); Saturation versus NIHSS score: \( R = −0.5 \ p < .01 \)
Differences in the results of routine inflammatory markers or fever on admission between patients with and without COVID-19 were not found in our cohort. However, similarly to previous authors, we found higher levels of D-dimers in patients with COVID-19. Formerly, lower platelet counts and higher level of D-dimers in the group of infected patients with AIS from Wuhan were reported. Also majority of the patients treated with IVT from United States described in case series by Caineiro et al had high level of D-dimers, and only 2 patients had high level of fibrinogen.

Stroke-associated pneumonia often negatively influences the prognosis of stroke patients. Pneumonia occurred more frequently in our patients with COVID-19. In patients with stroke and pneumonia, the saturation decreases more often than in patients without pneumonia. Almost 20% patients with COVID-19 have hypoxic respiratory failure.

We showed that stroke survivors functionally independent on discharge were characterized a higher baseline percentage of saturation on admission than patients with mRS 3–6 pts. However, similarly to the group from Wuhan, blood oxygen saturation was significantly lower in those patients who died.

The severity of the neurological condition and the accompanying lung infection prolonged the patients' stay in the hospital, which was pointed out in previous publications.

First of all, this was an observational study of only four regional stroke centres and, consequently, the group of analysed patients was not large. Thus, small size of the study may mask the results and lack of statistical significance. Although the data collection was conducted in a prospective manner and included all patients admitted within the observation period. Second, the treatment results were only limited to the in-hospital period, and long-term outcome has not been assessed. However, as it has been recently reported, independence on discharge may predict 90-Day Outcome after Thrombolysis.

5 | CONCLUSION

Based on our results, we suggest that patients with AIS infected COVID-19 may be safely treated with IVT in routine practise. However, when treating patients with COVID, one should strive to achieve the improvement in blood saturation, whose decrease can adversely affect the in-hospital outcome. SARS-CoV-2 infection prolongs length of stay in hospital after IVT.

CONFLICT OF INTEREST

P. Sobolewski has had lectureship fees covered by Boehringer-Ingelheim, Ever Pharma, Allergan and travel expenses to scientific conferences covered by Boehringer-Ingelheim, Ipsen and Ever Pharma and Angels Initiative. W. Brola has received speaker fees and/or served on Advisory Boards by Bayer, Biogen, Sanofi Genzyme, Merck, Novartis and Roche. He also received support for congress participation, travel and accommodation grants from Biogen, Merck, Roche and Sanofi Genzyme. G. Kozera’s research activities have been funded by the Ministry of Science and High Education, Poland, Office of the Governor of Pomerania, Poland; he has received speaker’s honoraria from the Boehringer-Ingelheim, Everpharma, Bayer and Pfizer and Angels Initiative. L. Bieniaszewski has been funded by the Ministry of Science and High Education, Poland, Poland. J. Antecki and M. Fudala declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS

PS and GK conceived the study. PS and GK wrote and distributed the protocol, designed the case report form and registration log, received the case report forms and uploaded them into the database. PS, JA, WB and MF extracted data from clinical records and completed case report forms. GK and LB performed statistical analyses. PS and GK wrote the manuscript. JA, WB, MF and LB were the members of the Core Writing Group and critically reviewed the protocol, case report form and manuscript. All authors critically reviewed the manuscript and approved the final version.

ETHICAL APPROVAL

The ethics committee approved all data of analysis (Ethics Committee of Jan Kochanowski University in Kielce).

DATA AVAILABILITY STATEMENT

Data are available on reasonable request, subject to restrictions imposed by patient confidentiality.

ORCID

Piotr Sobolewski https://orcid.org/0000-0003-4646-1702
Jacek Antecki https://orcid.org/0000-0002-8667-7615
Waldemar Brola https://orcid.org/0000-0002-7955-3454
Małgorzata Fudala https://orcid.org/0000-0002-0884-8175
Leszek Bieniaszewski https://orcid.org/0000-0001-6237-521X
Grzegorz Kozera https://orcid.org/0000-0001-7704-2434

REFERENCES

1. Hess DC, Eldashwan W, Rutkowski E. COVID-19-Related Stroke. *Transl Stroke Res*. 2020;11(3):322-325. https://doi.org/10.1007/s12975-020-00818-9
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
3. Qureshi AI, Abd-Allah F, Al-Senani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel. *Int J Stroke*. 2020;15(5):540-554. https://doi.org/10.1177/1747493020923234. Erratum in: Int J Stroke 2020 May3; https://doi.org/10.1177/1747493020935396
4. Perry RJ, Smith CJ, Roffe C, et al. SETICOS collaborators. Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study. *J Neurol Neurosurg Psychiatry*. 2020;92(3):242-248. https://doi.org/10.1136/jnnp-2020-324927
5. Powers W, Rabinstein A, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart
6. Boulanger JM, Lindsay MP, Gubitz G, et al. Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th edition, update 2018. Int J Stroke. 2018;13:949-984. https://doi.org/10.1177/1747493018786616

7. Nogueira RG, Qureshi MM, Abdalkader M, et al. SVIN COVID-19 global stroke registry. Global impact of COVID-19 on stroke care and IV thrombolysis. Neurology. 2021;96:e2824-e2838. https://doi.org/10.1221/WNL.00000000000011885

8. Wang J, Chaudhry SA, Tahsili-Fahadan P, et al. The impact of COVID-19 on acute ischemic stroke admissions: Analysis from a community-based tertiary care center. J Stroke Cerebrovasc Dis. 2020;29:105344. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105344

9. Wallace AN, Asif KS, Sahlein DH, et al. Patient characteristics and outcomes associated with decline in stroke volumes during the early COVID-19 pandemic. J Stroke Cerebrovasc Dis. 2021;30:105569. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105569

10. Koge J, Shiozawa M, Toyoda K. Acute stroke care in the COVID-19 Era: Experience at a comprehensive stroke center in Japan. Front Neurol. 2021;11:611504. https://doi.org/10.3389/fneur.2020.611504

11. Gori AM, Giusti B, Piccardi B, et al. Inflammatory and metalloproteinase profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis. J Cereb Blood Flow Metab. 2017;37(9):3253-3261. https://doi.org/10.1017/SCB.2017.695572

12. Bruening T, Al-Khaled M. Stroke-associated pneumonia in thrombolyzed patients: incidence and outcome. J Stroke Cerebrovasc Dis. 2015;24(8):1724-1729. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.03.045

13. Sangalli D, Polonia V, Colombo D, et al. A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients. Neuroradiology. 2020;62(4):2325-2329. https://doi.org/10.1007/s00033-019-01847-4

14. CoCOC, Yu JRT, Laxamana LC, David-Ona DIA. Intravenous thrombolysis for stroke in a COVID-19 positive Filipino patient, a case report. J Clin Neurosci. 2020;77:234-236. https://doi.org/10.1016/j.jcn.2020.04.019

15. Cappelari M, Zini A, Sangalli D, et al. Thrombolysis and bridging therapy in patients with acute ischemic stroke and Covid-19. Eur J Neurol. 2020;27(12):2641-2645. https://doi.org/10.1111/ene.14511

16. Carneiro T, Dashkoff J, Leung LY, et al. Intravenous TPA for acute ischemic stroke in patients with COVID-19. J Stroke Cerebrovasc Dis. 2020;29(11):105201. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105201

17. Błażejewska-Hyżorek B, Czernuszenko A, Członkowska A, et al. Post-pandemic stroke care: what has changed in the Polish stroke care system? Postepy Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego. Neurol Neurochir Pol. 2020;52(6):19-26. https://doi.org/10.1214/JNN.2020.004907

18. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training NINDS TPA stroke study group. Stroke. 1994;25(11):2220-2226. https://doi.org/10.1161/01.str.25.11.2220

19. Bonita R, Beaglehole R. Recovery of motor function after Stroke. Stroke. 1988;19(12):1497-1500. https://doi.org/10.1161/01.str.19.12.1497

20. Hacke W, Kaste M, Bluhmki E, et al. for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischaemic stroke. N Engl J Med. 2005;359(13):1317-1329. https://doi.org/10.1056/NEJMoa0804656

21. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24(1):35-41. https://doi.org/10.1161/01.str.24.1.35

22. Zhou Y, Hong C, Chang J, et al. Intravenous thrombolysis for acute ischemic stroke during COVID-19 pandemic in Wuhan, China: a multicentre, retrospective cohort study. J Neurol Neurosurg Psychiatry. 2021;92(2):226-228. https://doi.org/10.1136/jnnp-2020-324014

23. Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: The global COVID-19 stroke registry. Stroke. 2020;51(9):e254-e258. https://doi.org/10.1161/STROKEAHA.120.031208

24. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: A systematic review and meta-analysis. Int J Stroke. 2021;16(2):137-149. https://doi.org/10.1177/1747493020977292

25. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. American heart association stroke council and council on epidemiology and prevention. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A statement for healthcare professionals from the American heart association/american stroke association. Stroke. 2016;47(2):581-641. https://doi.org/10.1161/STR.0000000000000086

26. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.105924

27. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72134 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(12):1239-1242. https://doi.org/10.1001/jama.2020.2648

28. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J. 2020;133(11):1261-1267. https://doi.org/10.1097/CMP.0000000000000824

29. Akhtar N, Abid FB, Kamran S, et al. Characteristics and comparison of 32 COVID-19 and non-COVID-19 ischemic strokes and historical stroke patients. J Stroke Cerebrovasc Dis. 2021;30(1):105435. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105435

30. Wijeratne T, Sales CA, Crewther SG, Nguyen V, Karimi L. First austral case of good recovery of a COVID-19 patient with severe neurological symptoms post prolonged hospitalization. Cureus. 2021;12(9):e10366. https://doi.org/10.7759/cureus.10366

31. Bautista A, Meyer D, Meyer B. Novel definition of stroke good responders "predicts 90-day outcome after thrombolysis". J Stroke Cerebrovasc Dis. 2019;28(12):104422. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104422

How to cite this article: Sobolewski P, Antecki J, Brola W, Fudala M, Bieniaszewski L, Kozera G. Systemic thrombolysis in ischaemic stroke patients with COVID-19. Acta Neurol Scand. 2022;145:47–52. https://doi.org/10.1111/ane.13520